DATE/TIME
September 26, 1:30 – 2:00 PM EST
TOPIC
Critical Trends and Growth in Biopharma Contract Manufacturing: Returning to Near Normal
SPEAKER
Eric Langer
Managing Partner, BioPlan Associates, Inc.
ABSTRACT
This session will discuss critical trends and growth in biopharma contract manufacturing by exploring study results from 250 biopharma manufacturers and their CDMOs. Findings cover where outsourcing has trended post-COVID, and how recent legislation, major acquisitions and other factors may be affecting available capacity and demand.
BIO
Eric Langer has over 30 years of experience in biotechnology and life sciences international marketing, management, market assessment, and publishing. He has held senior management and marketing positions at biopharmaceutical supply companies. He is an experienced biotechnology strategist, marketing practitioner, publisher, and researcher. He has published, edited and authored numerous books, reports, and major studies on topics including: Advances in Biopharmaceutical Technology in China, Advances in Large-scale Biopharmaceutical Manufacturing, Biopharmaceuticals in the U.S. Market, cell culture reports, media, sera, tissue engineering, stem cells, diagnostic products, blood products, genetics, DNA/PCR purification, blood components, and many others. He lectures extensively on marketing, pricing and channel management topics, and teaches at Johns Hopkins University and American University on Biotechnology Marketing, Marketing Management, Services Marketing, Advertising Strategy, and Bioscience Communication. In 1989 he co-founded BioPlan Associates, Inc. He has launched and managed marketing programs for product lines ranging from $500k to $500 million.
